Patents Assigned to Asahi Kasei Pharma Corporation
  • Publication number: 20240025893
    Abstract: A compound represented by the general formula (1) or a salt thereof, which has a superior IRAK-4 inhibitory activity, and is useful as active ingredients of medicaments for prophylactic treatment and/or therapeutic treatment of diseases relating to IRAK-4 inhibition.
    Type: Application
    Filed: September 30, 2020
    Publication date: January 25, 2024
    Applicants: Asahi Kasei Pharma Corporation, Vernalis (R&D) Limited
    Inventors: Koichiro ARAI, Kenichiro TAKABA, Masakazu ATOBE, Misato TAKASHIMA, Naomi AONO, Andrew John POTTER, Daniel Paul MADDOX
  • Publication number: 20230357271
    Abstract: A compound represented by the general formula (1) or a salt thereof, which has a superior IRAK-4 inhibitory activity, and is useful as active ingredients of medicaments for prophylactic treatment and/or therapeutic treatment of diseases relating to IRAK-4 inhibition.
    Type: Application
    Filed: September 30, 2020
    Publication date: November 9, 2023
    Applicants: Asahi Kasei Pharma Corporation, Vernalis (R&D) Limited
    Inventors: Takahiko ITO, Misato TAKASHIMA, Masakazu ATOBE, Koichiro ARAI, Tomohisa TOYAMA, Yu YOSHII, Andrew John POTTER, Daniel Paul MADDOX, Stuart RAY, Nicolas FOLOPPE
  • Publication number: 20230125968
    Abstract: The present invention addresses the problem of providing a method for producing nicotinamide mononucleotide, that produces nicotinamide mononucleotide using a single enzyme and using nucleoside monophosphate, pyrophosphate, and nicotinamide as starting materials. This problem is solved by a nicotinamide mononucleotide production method that includes at least the following steps 1) and 2): 1) a first step of producing phosphoribosyl diphosphate by the action of substantially one enzyme on nucleoside monophosphate and pyrophosphate; and 2) a second step of producing nicotinamide mononucleotide by the action of only substantially the aforementioned one enzyme on nicotinamide and the phosphoribosyl diphosphate that is the product of the first step.
    Type: Application
    Filed: October 26, 2022
    Publication date: April 27, 2023
    Applicant: Asahi Kasei Pharma Corporation
    Inventors: Takeshi MATSUOKA, Tatsuya HIRATA, Masaru YAMAKOSHI
  • Patent number: 11439633
    Abstract: The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the P2X7 receptor.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: September 13, 2022
    Assignees: RaQualia Pharma Inc., Asahi Kasei Pharma Corporation
    Inventors: Yoshimasa Arano, Kazuki Toyoshima, Toshihiko Sone, Koki Matsubara
  • Patent number: 11077100
    Abstract: The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the P2X7 receptor.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: August 3, 2021
    Assignees: RaQualia Pharma Inc., Asahi Kasei Pharma Corporation
    Inventors: Hirohide Noguchi, Yoshimasa Arano, Kazuo Ando, Kazuki Toyoshima, Toshihiko Sone
  • Publication number: 20210188837
    Abstract: A novel compound represented by the following general formula (1), or a salt thereof, which has a superior EP4 receptor agonist activity, and a medicament containing the compound or a salt thereof as an active ingredient, which can be used for promotion of osteogenesis, therapeutic treatment and/or promotion of healing of fracture and the like.
    Type: Application
    Filed: March 4, 2021
    Publication date: June 24, 2021
    Applicant: Asahi Kasei Pharma Corporation
    Inventors: Daisuke SHIKANAI, Noriko ISHIGURO, Osamu OMORI
  • Publication number: 20210085667
    Abstract: The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the P2X7 receptor.
    Type: Application
    Filed: December 4, 2020
    Publication date: March 25, 2021
    Applicants: RaQualia Pharma Inc., Asahi Kasei Pharma Corporation
    Inventors: Hirohide NOGUCHI, Yoshimasa ARANO, Kazuo ANDO, Kazuki TOYOSHIMA, Toshihiko SONE, Koki MATSUBARA
  • Publication number: 20200405706
    Abstract: The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the P2X7 receptor.
    Type: Application
    Filed: March 13, 2018
    Publication date: December 31, 2020
    Applicants: RaQualia Pharma Inc., Asahi Kasei Pharma Corporation
    Inventors: Hirohide NOGUCHI, Yoshimasa ARANO, Kazuo ANDO, Kazuki TOYOSHIMA, Toshihiko SONE, Koki MATSUBARA
  • Publication number: 20200347046
    Abstract: A novel compound represented by the following general formula (1), or a salt thereof, which has a superior EP4 receptor agonist activity, and a medicament containing the compound or a salt thereof as an active ingredient, which can be used for promotion of osteogenesis, therapeutic treatment and/or promotion of healing of fracture and the like.
    Type: Application
    Filed: December 25, 2018
    Publication date: November 5, 2020
    Applicant: Asahi Kasei Pharma Corporation
    Inventors: Daisuke SHIKANAI, Noriko ISHIGURO, Osamu OMORI
  • Publication number: 20200101139
    Abstract: An object of the present invention is to provide an effective and safe medicament having effects for mitigating conditions and/or suppressing onset of a peripheral neuropathy induced by administration of an anti-malignant tumor agent, oxaliplatin, in a human cancer patient receiving an anti-malignant tumor treatment with oxaliplatin. There is provided a medicament for mitigating conditions and/or suppressing onset of a peripheral neuropathy induced by oxaliplatin in an anti-malignant tumor treatment consisting of repetition of a single cycle comprising intravenous administration of oxaliplatin to a human cancer patient and following drug withdrawal, which contains thrombomodulin for intravenously administering 0.06 mg/kg of thrombomodulin once per said single cycle of the treatment on the first day of each said cycle as an active ingredient.
    Type: Application
    Filed: October 18, 2019
    Publication date: April 2, 2020
    Applicant: Asahi Kasei Pharma Corporation
    Inventors: Takumi SAKAI, Genichi KUSAKAWA, Yugo UCHIDA
  • Patent number: 9555080
    Abstract: A medicament for therapeutic treatment and/or improvement of sepsis in a patient with severe sepsis accompanied with one or more organ dysfunctions, wherein a value of International Normalized Ratio (INR) of a plasma specimen obtained from said patient is more than 1.4, which comprises thrombomodulin as an active ingredient.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: January 31, 2017
    Assignee: Asahi Kasei Pharma Corporation
    Inventors: Kazuhisa Tsuruta, Yoshikazu Aoki, Yutaka Osawa, Inder Kaul
  • Patent number: 9006225
    Abstract: A pharmaceutical composition which includes a compound represented by the general formula (I): or a salt thereof, and a pharmaceutically acceptable carrier, wherein the composition does not substantially contain a reducing sugar and/or a carrier containing a reducing sugar as an ingredient as the pharmaceutically acceptable carrier, or when the composition contains a reducing sugar and/or a carrier containing a reducing sugar as an ingredient as the pharmaceutically acceptable carrier, contact of the reducing sugar and the compound represented by the general formula (I) or a salt thereof is eliminated.
    Type: Grant
    Filed: January 16, 2009
    Date of Patent: April 14, 2015
    Assignee: Asahi Kasei Pharma Corporation
    Inventor: Kazumi Suzuki
  • Patent number: 8952137
    Abstract: A method is provided for producing soluble thrombomodulin substantially not containing a denatured product of the soluble thrombomodulin that is generated under acidic conditions, which comprises: subjecting the soluble thrombomodulin-containing material to an anion exchanger or hydroxyapatite; and carrying out linear gradient elution, stepwise gradient elution, or gradient elution in which linear gradient elution is combined with stepwise gradient elution under separation conditions in which the denatured product of the soluble thrombomodulin can be separated, wherein the gradient is a salt concentration gradient, so as to obtain an elution fraction containing soluble thrombomodulin that does not substantially contain the denatured product of the soluble thrombomodulin, either (a) after the position of a fraction has previously been confirmed, or (b) while confirming the elution fraction.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: February 10, 2015
    Assignee: Asahi Kasei Pharma Corporation
    Inventor: Susumu Ohigashi
  • Patent number: 8772239
    Abstract: A medicament for therapeutic treatment and/or improvement of sepsis in a patient with severe sepsis accompanied with one or more organ dysfunctions, wherein a value of International Normalized Ratio (INR) of a plasma specimen obtained from said patient is more than 1.4, which comprises thrombomodulin as an active ingredient.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: July 8, 2014
    Assignee: Asahi Kasei Pharma Corporation
    Inventors: Kazuhisa Tsuruta, Yoshikazu Aoki, Yutaka Osawa, Inder Kaul
  • Patent number: 8772327
    Abstract: A compound represented by the following general formula (1) or a salt thereof, which has superior inhibitory activity against type 4 PLA2, and thus has prostaglandin and/or leucotriene production suppressing action [X represents a halogen atom, an alkyl group which may be substituted, or the like, Y represents hydrogen atom or an alkyl group which may be substituted, and Z represents hydrogen atom or an alkyl group which may be substituted].
    Type: Grant
    Filed: October 17, 2012
    Date of Patent: July 8, 2014
    Assignee: Asahi Kasei Pharma Corporation
    Inventors: Kohei Morita, Hiroshi Kuriyama, Kosuke Tanaka
  • Patent number: 8664243
    Abstract: (S)-1-(4-Chloro-5-isoquinolinesulfonyl)-3-(methylamino)pyrrolidine monohydrochloride and a crystal thereof, and a crystal of the aforementioned monohydrochloride having a major peak or peaks at one or more positions selected from the group consisting of positions where 2?s are about 13.9°, 21.5°, 21.7°, 22.4°, 22.8°, 24.5° and 35.0° in a powder X-ray diffraction spectrum, which have excellent properties as active ingredient of a medicament for prophylactic and/or therapeutic treatment of glaucoma and the like.
    Type: Grant
    Filed: June 27, 2012
    Date of Patent: March 4, 2014
    Assignee: Asahi Kasei Pharma Corporation
    Inventors: Hitoshi Kida, Koki Matsubara, Shunsuke Kaneko
  • Patent number: 8476259
    Abstract: Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and/or preventing pulmonary arterial hypertension and/or stable angina. More particularly, aspects of the present invention are related to therapeutic combinations comprising a Rho-kinase inhibitor, such as fasudil, and one or more additional compounds selected from the group consisting of prostacyclins, such as iloprost, endothelin receptor antagonists, PDE inhibitors, calcium channel blockers, 5-HT2A antagonists, such as sarpogrelate, selective serotonin reuptake inhibitors, such as fluoxetine, statins, and vascular remodeling modulators, such as Gleevec.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: July 2, 2013
    Assignee: Asahi Kasei Pharma Corporation
    Inventor: Benson Fong
  • Patent number: 8415372
    Abstract: A compound represented by the formula (1) [A represents a nitrogen-containing saturated ring; m represents an integer of 0 to 2; n represents an integer of 1 to 4; G1 represents hydrogen atom, chlorine atom, hydroxyl group, an alkoxy group, or amino group; G2 represents a halogen atom, hydroxyl group, cyano group, carboxy group, an alkyl group, an alkenyl group, and the like; G3 represents hydrogen atom, a halogen atom, hydroxyl group, cyano group, carboxy group, an alkyl group, an alkenyl group, and the like; G4 represents hydroxyl group, or —N(R1)(R2) (R1 and R2 represent hydrogen atom, an alkyl group, an aralkyl group, an alkenyl group, an alkynyl group, or a saturated heterocyclic group); G5 is a substituent on a ring-constituting carbon atom of A, and represents hydrogen atom, fluorine atom, or an alkyl group] or a salt thereof, or a derivative thereof that is a prodrug, which potently inhibits Rho kinase.
    Type: Grant
    Filed: February 27, 2007
    Date of Patent: April 9, 2013
    Assignee: Asahi Kasei Pharma Corporation
    Inventors: Rintaro Yamada, Minoru Seto
  • Patent number: 8334314
    Abstract: A compound represented by the following general formula (1) or a salt thereof, which has superior inhibitory activity against type 4 PLA2, and thus has prostaglandin and/or leucotriene production suppressing action [X represents a halogen atom, an alkyl group which may be substituted, or the like, Y represents hydrogen atom or an alkyl group which may be substituted, and Z represents hydrogen atom or an alkyl group which may be substituted].
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: December 18, 2012
    Assignee: Asahi Kasei Pharma Corporation
    Inventors: Kohei Morita, Hiroshi Kuriyama, Kosuke Tanaka
  • Patent number: 8304443
    Abstract: Compounds represented by the Formula (A-1) and the Formula (1) or salt thereof are provided. The compounds represented by the Formula (A-1) and the Formula (1) or salt thereof have a ?3 adrenergic receptor agonist activity, and therefore are useful as an agent for the prevention and treatment of diabetes, obesity, hyperlipidemia, depression, biliary stone, a disorder derived from hyperactivity of biliary tract, a disorder derived from hyperactivity of digestive tract, interstitial cystitis, overactive bladder, urinary incontinence or a disorder derived from decreased tear secretion, etc.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: November 6, 2012
    Assignee: Asahi Kasei Pharma Corporation
    Inventors: Seiji Nakano, Akifumi Morimoto, Yasuhiro Wada